+

PE20110065A1 - COMPOSITIONS AND METHODS FOR PREPARING IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS SEROTYPES 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE - Google Patents

COMPOSITIONS AND METHODS FOR PREPARING IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS SEROTYPES 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE

Info

Publication number
PE20110065A1
PE20110065A1 PE2010000421A PE2010000421A PE20110065A1 PE 20110065 A1 PE20110065 A1 PE 20110065A1 PE 2010000421 A PE2010000421 A PE 2010000421A PE 2010000421 A PE2010000421 A PE 2010000421A PE 20110065 A1 PE20110065 A1 PE 20110065A1
Authority
PE
Peru
Prior art keywords
compositions
polysaccharide
staphylococcus aureus
methods
capsular polysaccharide
Prior art date
Application number
PE2010000421A
Other languages
Spanish (es)
Inventor
Stephen John Freese
Annaliesa Anderson
Viliam Pavliak
Jansen Kathrin Ute
Dodge Ingrid Lea
Scott Tracy Dee
Nanra Jasdeep Singh
A Krishna Prasad
Bruce Arthur Green
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PE20110065A1 publication Critical patent/PE20110065A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN CONJUGADO INMUNOGENICO DE POLISACARIDO-PROTEINA QUE COMPRENDE UN POLISACARIDO CAPSULAR DE SEROTIPO 8 O 5 DE STAPHYLOCOCCUS AUREUS AISLADO CONJUGADO A UNA PROTEINA PORTADORA, DONDE EL POLISACARIDO TIENE UN PESO MOLECULAR DE ENTRE 20 KDa Y 1000 KDa Y LA PROTEINA PORTADORA ES CRM197, LA CUAL ESTA LIGADA COVALENTEMENTE AL POLISACARIDO MEDIANTE UN ENLACE DE CARBAMATO, UN ENLACE AMIDA O AMBOS. ASIMISMO, LA PROTEINA CMR197 COMPRENDE DE 8 A 15 LISINAS ENLAZADAS COVALENTEMENTE AL POLISACARIDO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION INMUNOGENICA Y A UN METODO DE PREPARACIONREFERRING TO AN IMMUNOGENIC CONJUGATE OF POLYSACCHARIDE-PROTEIN INCLUDING A CAPSULAR POLYSACCHARIDE OF SEROTYPE 8 OR 5 OF STAPHYLOCOCCUS AUREUS ISOLATED CONJUGATED TO A CARRIER PROTEIN, WHERE THE POLYSACCHARIDE HAS A KDa WEIGHT OF 1000 KDaMOLECULAR PROTEIN AND KDa19 IN 1000 KDaMOLECULAR CARRIER WHICH IS COVALENTLY LINKED TO THE POLYSACCHARIDE THROUGH A CARBAMATE LINK, AN AMIDA LINK, OR BOTH. ALSO, PROTEIN CMR197 INCLUDES 8 TO 15 LYSINES COVALENTLY LINKED TO POLYSACCHARIDE. IT ALSO REFERS TO AN IMMUNOGENIC COMPOSITION AND A METHOD OF PREPARATION

PE2010000421A 2009-06-22 2010-06-22 COMPOSITIONS AND METHODS FOR PREPARING IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS SEROTYPES 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE PE20110065A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21915109P 2009-06-22 2009-06-22
US21914309P 2009-06-22 2009-06-22

Publications (1)

Publication Number Publication Date
PE20110065A1 true PE20110065A1 (en) 2011-01-31

Family

ID=43599164

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010000421A PE20110065A1 (en) 2009-06-22 2010-06-22 COMPOSITIONS AND METHODS FOR PREPARING IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS SEROTYPES 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE

Country Status (22)

Country Link
US (2) US9125951B2 (en)
EP (2) EP2445523B1 (en)
JP (4) JP2012530785A (en)
KR (2) KR20140119165A (en)
CN (1) CN102625713A (en)
AR (1) AR077190A1 (en)
AU (1) AU2010301043B2 (en)
BR (1) BRPI1011753B8 (en)
CA (1) CA2766418C (en)
CO (1) CO6480930A2 (en)
ES (2) ES2959890T3 (en)
IL (1) IL217085B (en)
MX (1) MX2012000045A (en)
MY (1) MY158231A (en)
NZ (1) NZ597191A (en)
PE (1) PE20110065A1 (en)
PH (2) PH12015502508A1 (en)
RU (1) RU2531234C2 (en)
SA (1) SA114350400B1 (en)
SG (2) SG177310A1 (en)
TW (2) TW201544119A (en)
WO (1) WO2011041003A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
CA2779798C (en) * 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
US9060965B2 (en) * 2009-10-30 2015-06-23 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 capsular saccharides
AR091902A1 (en) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF A PROLONGED INSULIN CONJUGATE
PT3421051T (en) 2012-08-16 2020-06-26 Pfizer Glycoconjugation processes and compositions
US9580734B2 (en) 2012-11-21 2017-02-28 Serum Institute Of India Private Ltd. Production of high yields of bacterial polysaccharides
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
US20160324949A1 (en) * 2014-01-21 2016-11-10 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US10828370B2 (en) 2014-05-12 2020-11-10 Purdue Research Foundation Selectin and ICAM/VCAM peptide ligand conjugates
JP6666901B2 (en) 2014-08-08 2020-03-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Modified host cells for use in bioconjugate production
WO2016091904A1 (en) 2014-12-10 2016-06-16 Glaxosmithkline Biologicals Sa Method of treatment
MX368897B (en) * 2015-05-04 2019-10-21 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof.
KR20250058066A (en) * 2015-07-21 2025-04-29 화이자 인코포레이티드 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX387200B (en) * 2016-02-15 2025-03-18 Hipra Scient S L U STREPTOCOCCUS UBERIS EXTRACT AS AN IMMUNOGENIC AGENT.
JP2019508468A (en) * 2016-03-15 2019-03-28 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドＭｓｄ Ｗｅｌｌｃｏｍｅ Ｔｒｕｓｔ Ｈｉｌｌｅｍａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｖｔ．Ｌｔｄ． Novel polysaccharide-protein conjugate and method for obtaining it
US11090374B2 (en) 2017-02-24 2021-08-17 Merck Sharp & Dohme Corp. Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
CN111065387B (en) 2017-09-07 2023-08-25 默沙东有限责任公司 Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328040B2 (en) 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
KR20210005161A (en) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 Method for Producing Streptococcus pneumoniae Capsular Polysaccharide Carrier Protein Conjugate from Riosphere
KR20210005158A (en) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 Method for producing a capsular polysaccharide carrier protein conjugate to Streptococcus pneumoniae
JP7397000B2 (en) * 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー Method for providing a homogeneous solution of lyophilized mutant diphtheria toxin in dimethyl sulfoxide
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
KR20220144393A (en) 2020-02-21 2022-10-26 화이자 인코포레이티드 sugar purification
CN111228478A (en) * 2020-02-25 2020-06-05 江南大学 Application of Trisaccharide Repeating Unit Oligosaccharide Chain in Preparation of Staphylococcus aureus Vaccine
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022249107A2 (en) * 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US150688A (en) 1874-05-12 Improvement in centrifugal machines
US4134214A (en) 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE8405493D0 (en) 1984-11-01 1984-11-01 Bror Morein IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (en) 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
CA2047031A1 (en) 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
WO1993009811A1 (en) 1991-11-22 1993-05-27 Univax Biologics, Inc. TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)
IT1253009B (en) 1991-12-31 1995-07-10 Sclavo Ricerca S R L DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES
ATE280235T1 (en) 1993-03-05 2004-11-15 Wyeth Corp PLASMID FOR PRODUCING CRM PROTEIN AND DIPHTHERIA TOXIN
KR100376361B1 (en) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 How to activate soluble carbohydrates using new cyanating reagents for the production of immunogenic constructs
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996014873A2 (en) * 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
BE1008978A5 (en) 1994-12-27 1996-10-01 Solvay Adjuvants for vaccines.
AU725279B2 (en) * 1995-06-07 2000-10-12 Alberta Research Council Inc. Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
JP4235262B2 (en) 1997-06-12 2009-03-11 シンエツ・バイオ，インコーポレイテッド Production of non-native bacterial exopolysaccharides in recombinant bacterial hosts
AU8407298A (en) 1997-07-17 1999-02-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hexadecasaccharide-protein conjugate vaccine for (shigella dysenteriae) type
JP4486748B2 (en) 1997-11-26 2010-06-23 インヒビテツクス，インコーポレイテツド Extracellular matrix binding protein from Staphylococcus aureus
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
DE69940404D1 (en) 1998-08-31 2009-03-26 Inhibitex Inc Multicomponent vaccines against Staphylococcus aureus
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
AR022963A1 (en) 1999-03-19 2002-09-04 Smithkline Beecham Biolog VACCINE
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
CA2391316A1 (en) 2000-03-22 2001-09-27 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
AT410635B (en) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh VACCINE COMPOSITION
KR20030096292A (en) * 2001-03-27 2003-12-24 덴드레온 샌 디에고 엘엘씨 Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
JP2004535187A (en) 2001-06-07 2004-11-25 ワイス・ホールデイングス・コーポレーシヨン Mutant forms of cholera holotoxin as adjuvants
EP1404279A4 (en) 2001-06-07 2007-08-08 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CA2351018A1 (en) 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
FR2828404B1 (en) 2001-08-10 2005-07-15 Neovacs COMPOSITE SUPERIMMUNOGEN FOR BIFUNCTIONAL VACCINE USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH STROMAL TISSUE DISORDER
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US20030092062A1 (en) * 2001-10-24 2003-05-15 Reddy M. Parameswara Immobilizing biological molecules
NZ535968A (en) * 2002-03-26 2006-08-31 Chiron S Modified saccharides having improved stability in water
TW200306314A (en) 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CN100351260C (en) 2002-11-12 2007-11-28 布赖汉姆妇女医院 Polysaccharide vaccine for staphylococcal infections
JP4078417B2 (en) 2003-03-04 2008-04-23 独立行政法人産業技術総合研究所 Oligopeptidase from thermophile
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CA2510040C (en) * 2003-05-23 2012-01-03 Nektar Therapeutics Al, Corporation Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
SI1701968T1 (en) 2003-12-17 2015-08-31 Wyeth Llc Immunogenic peptide carrier conjugates and methods of producing same
US7537766B2 (en) 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
AU2005287502B2 (en) 2004-09-22 2011-12-01 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
ES2377075T5 (en) * 2005-06-27 2016-04-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
AR060188A1 (en) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa CONJUGATION PROCEDURE
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
EP3141261A1 (en) * 2006-03-30 2017-03-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
FR2899110A1 (en) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Immunogenic composition, useful for immunizing against Staphylococcus aureus infection, comprises capsular polysaccharide of type 8 and 5 of Staphylococcus aureus strain overproducing type 8 and/or type 5, respectively
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2129693B1 (en) 2007-03-23 2016-12-07 Wyeth LLC Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
JP5689687B2 (en) 2008-03-05 2015-03-25 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ Method for stabilizing an adjuvant-containing vaccine composition
AU2010264538B2 (en) * 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US9060965B2 (en) 2009-10-30 2015-06-23 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 capsular saccharides
HUE047263T2 (en) 2010-12-22 2020-04-28 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens

Also Published As

Publication number Publication date
KR101774062B1 (en) 2017-09-01
EP2445523A2 (en) 2012-05-02
EP3461496B1 (en) 2023-08-23
JP2013237693A (en) 2013-11-28
SA114350400B1 (en) 2016-05-26
US9623100B2 (en) 2017-04-18
WO2011041003A9 (en) 2011-06-09
RU2531234C2 (en) 2014-10-20
AU2010301043A1 (en) 2012-01-19
BRPI1011753B1 (en) 2021-03-02
RU2011152045A (en) 2013-07-27
TW201544119A (en) 2015-12-01
CN102625713A (en) 2012-08-01
IL217085A0 (en) 2012-02-29
US20160022798A1 (en) 2016-01-28
WO2011041003A2 (en) 2011-04-07
EP2445523B1 (en) 2019-04-17
IL217085B (en) 2018-10-31
CO6480930A2 (en) 2012-07-16
JP2016053051A (en) 2016-04-14
SG10201406432RA (en) 2014-11-27
CA2766418A1 (en) 2011-04-07
CA2766418C (en) 2016-03-29
TWI505834B (en) 2015-11-01
TW201110977A (en) 2011-04-01
US20120276137A1 (en) 2012-11-01
US9125951B2 (en) 2015-09-08
MX2012000045A (en) 2012-01-30
NZ597191A (en) 2013-11-29
EP3461496A1 (en) 2019-04-03
AU2010301043B2 (en) 2014-01-09
WO2011041003A3 (en) 2011-10-27
KR20120048568A (en) 2012-05-15
ES2729934T3 (en) 2019-11-07
JP6393804B2 (en) 2018-09-19
AR077190A1 (en) 2011-08-10
JP2017179378A (en) 2017-10-05
PH12021551159A1 (en) 2022-02-21
ES2959890T3 (en) 2024-02-28
KR20140119165A (en) 2014-10-08
JP2012530785A (en) 2012-12-06
JP6153581B2 (en) 2017-06-28
MY158231A (en) 2016-09-15
SG177310A1 (en) 2012-02-28
BRPI1011753B8 (en) 2021-05-25
BRPI1011753A2 (en) 2016-03-29
PH12015502508A1 (en) 2019-06-03

Similar Documents

Publication Publication Date Title
PE20110065A1 (en) COMPOSITIONS AND METHODS FOR PREPARING IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS SEROTYPES 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE
AR116043A2 (en) COMPOSITION OF CONJUGATED VACCINE OF POLYSACCHARIDE-PNEUMOCOCCAL PROTEIN 15-VALENT
AR084158A1 (en) FORMULATIONS THAT MITIGATE THE AGGREGATION INDUCED BY AGMATION OF IMMUNOGENIC COMPOSITIONS
ZA201901170B (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
AR060187A1 (en) IMMUNOGENIC COMPOSITION
BR112020004509A8 (en) POLYSACCHARIDE-CARRIER PROTEIN CONJUGATE, IMMUNOGENIC COMPOSITION INCLUDING THE SAME AND USE OF SAID CONJUGATE
BR112020004471A8 (en) PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
MX379051B (en) IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF.
PE20071058A1 (en) STREPTOCOCCUS PNEUMONIAE VACCINE
FI3583947T3 (en) Capsular polysaccharides of Streptococcus pneumoniae and their conjugates
MX337528B (en) IMMUNOGENIC COMPOSITION THAT INCLUDES A SACRAMID CAPSULAR STAFFILOCÓCICO O-ACETYLATE AND A STAFILOCÓCICA PROTEIN.
CL2007003781A1 (en) Method for the preparation of an immunogenic conjugate comprising the polysaccharide of streptococcus pneumoniae serotype 1 covalently linked to a carrier protein; and process for preparing a multivalent polysaccharide-protein immunogenic composition.
BRPI0519232A2 (en) saccharide conjugate vaccines
AR092897A1 (en) IMMUNOGENIC COMPOSITIONS
EA201391788A1 (en) VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CL2012000744A1 (en) Process for preparing a type 5 or type 8 capsular polysaccharide conjugate of s. aureus and a carrier molecule; polysaccharide conjugate; and an immunogenic composition comprising it.
ZA202103560B (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
BRPI0915517B8 (en) method for producing a vi conjugate, conjugate, e, pharmaceutical composition
PE20080774A1 (en) IMMUNOGENIC COMPOSITION INCLUDING PNAG OF STAPHYLACCOCES CONJUGATED WITH A CARRIER PROTEIN AND CAPSULAR POLYSACCHARIDE OR OLIGOSACCHARIDE OF S. AUREUS

Legal Events

Date Code Title Description
FG Grant, registration
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载